Correction to: An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies (Emerging Microbes & Infections, (2020), 9, 1, (275-277), 10.1080/22221751.2020.1723441);An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies

Emerging Microbes and Infections

Volumn 9, Issue 1, 2020, Pages 275-277

  Jiang, Shibo ^a,b   Du, Lanying ^b   Shi, Zhengli ^c  

^a FUDAN UNIVERSITY   (China)

^b NEW YORK BLOOD CENTER   (United States)

^c WUHAN INSTITUTE OF VIROLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; COVID-19; EPITOPE; MONOCLONAL ANTIBODY; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VIRUS ANTIBODY;

AMINO TERMINAL SEQUENCE; BETACORONAVIRUS; CHINA; CORONAVIRUS DISEASE 2019; CORONAVIRUS INFECTION; EPIDEMIC; GENE SEQUENCE; HUMAN; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; NOTE; PHYLOGENY; PNEUMONIA; PRIORITY JOURNAL; REAL TIME REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION LOOP MEDIATED ISOTHERMAL AMPLIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARS CORONAVIRUS; SEA FOOD; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VIRUS DETECTION; VIRUS IDENTIFICATION; ANIMAL; BAT; COMMUNICABLE DISEASE; NUCLEIC ACID AMPLIFICATION; PATHOGENICITY; VIROLOGY; VIRUS PNEUMONIA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BETACORONAVIRUS; CHINA; CHIROPTERA; COMMUNICABLE DISEASES, EMERGING; CORONAVIRUS INFECTIONS; EPITOPES; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PHYLOGENY; PNEUMONIA, VIRAL;

EID: 85078834780     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1080/22221751.2020.1737363     Document Type: Erratum

References (13)

1. Lu H, Stratton, CW, Tang YW., Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle. J Med Virol. 2020;92. doi: 10.1002/jmv.25678
2. Chan, JF, Kok, KH, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from patients with acute respiratory disease in Wuhan, Hubei, China. Emerg Microbes Infect. 2020;9:221–236. doi: 10.1080/22221751.2020.1719902
3. Hu D, Zhu C, Ai L, et al. Genomic characterization and infectivity of a novel SARS-like coronavirus in Chinese bats. Emerg Microbes Infect. 2018;7:154.
4. Zhang N, Wang L, Deng X, et al. Recent advances in the detection of respiratory virus infection in humans. J Med Virol. 2020;92. DOI:10.1002/jmv.25674 doi: 10.1002/jmv.25611
5. Du L, He Y, Zhou Y, et al. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7:226–236. doi: 10.1038/nrmicro2090
6. Liu S, Xiao G, Chen Y, et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet. 2004;363:938–947. doi: 10.1016/S0140-6736(04)15788-7
7. Xia S, Yan L, Xu W, et al. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv. 2019;5:eaav4580. doi: 10.1126/sciadv.aav4580
8. Du L, Yang Y, Zhou Y, et al. MERS-CoV spike protein: a key target for antivirals. Expert Opin Ther Targets. 2017;21:131–143. doi: 10.1080/14728222.2017.1271415
9. Zhou Y, Yang Y, Huang J, et al. Advances in MERS-CoV vaccines and therapeutics based on the receptor-binding domain. Viruses. 2019;11:pii: E60. doi: 10.3390/v11010060
10. Du L, Tai W, Yang Y, et al. Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. Nat Commun. 2016;7:13473. doi: 10.1038/ncomms13473
11. Wang L, Shi W, Joyce MG, et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun. 2015;6:7712. doi: 10.1038/ncomms8712
12. Chen Y, Lu S, Jia H, et al. A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein. Emerg Microbes Infect. 2017;6:e37.
13. Zeng LP, Ge X-Y, Peng C, et al. Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses. Sci China Life Sci. 2017;60:1399–1402. doi: 10.1007/s11427-017-9189-3